Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Washington Post Publisher Will Lewis Steps Down After Layoffs
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 



